You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Parke Davis Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for PARKE DAVIS, and what generic and branded alternatives to PARKE DAVIS drugs are available?

PARKE DAVIS has one hundred approved drugs.



Summary for Parke Davis
US Patents:0
Tradenames:72
Ingredients:64
NDAs:100

Drugs and US Patents for Parke Davis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis PRE-SATE chlorphentermine hydrochloride TABLET;ORAL 014696-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Parke Davis CENTRAX prazepam CAPSULE;ORAL 018144-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Parke Davis NITROSTAT nitroglycerin INJECTABLE;INJECTION 070872-001 Jan 8, 1987 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Parke Davis NORLUTIN norethindrone TABLET;ORAL 010895-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Parke Davis METHYLTESTOSTERONE methyltestosterone TABLET;ORAL 084241-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Parke Davis PARACORT prednisone TABLET;ORAL 010962-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Parke Davis EUTHROID-0.5 liotrix (t4;t3) TABLET;ORAL 016680-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Parke Davis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Parke Davis FEMPATCH estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020417-001 Dec 3, 1996 4,906,463 ⤷  Try a Trial
Parke Davis FEMPATCH estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020417-001 Dec 3, 1996 5,006,342 ⤷  Try a Trial
Parke Davis CEREBYX fosphenytoin sodium INJECTABLE;INJECTION 020450-001 Aug 5, 1996 4,260,769 ⤷  Try a Trial
Parke Davis CHOLYBAR cholestyramine BAR, CHEWABLE;ORAL 071621-001 May 26, 1988 4,778,676 ⤷  Try a Trial
Parke Davis CEREBYX fosphenytoin sodium INJECTABLE;INJECTION 020450-001 Aug 5, 1996 4,925,860 ⤷  Try a Trial
Parke Davis CHOLYBAR cholestyramine BAR, CHEWABLE;ORAL 071739-001 May 26, 1988 4,778,676 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PARKE DAVIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 2005-10-19
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 2011-12-29
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.